We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+16%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$2.62M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
243
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
+$3.29M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$1.96M |
| 3 |
Apple
AAPL
|
+$1.92M |
| 4 |
Vaxcyte
PCVX
|
+$1.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$5.11M |
| 2 |
Amazon
AMZN
|
+$4.12M |
| 3 |
Airbnb
ABNB
|
+$2.92M |
| 4 |
Analog Devices
ADI
|
+$2.79M |
| 5 |
KE Holdings
BEKE
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HLVX
326
DELISTED
HilleVax
HLVX
| $8.84K | ﹤0.01% |
514
+62
| +14% | +$961 |
|
|
BCYC
327
Bicycle Therapeutics
BCYC
$284M
| $8.65K | ﹤0.01% |
339
-10
| -3% | -$232 |
|
328
Anavex Life Sciences
AVXL
$316M
| $8.61K | ﹤0.01% |
1,059
+2
| +0.2% | +$17 |
|
329
Dyne Therapeutics
DYN
$4.89B
| $8.6K | ﹤0.01% |
764
+58
| +8% | +$684 |
|
|
RAPT
330
DELISTED
RAPT Therapeutics
RAPT
| $8.41K | ﹤0.01% |
56
-2
| -3% | -$312 |
|
331
Novavax
NVAX
$1.31B
| $8.4K | ﹤0.01% |
1,131
-36
| -3% | -$283 |
|
332
ARS Pharmaceuticals
SPRY
$601M
| $8.32K | ﹤0.01% |
1,242
-28
| -2% | -$187 |
|
333
Seres Therapeutics
MCRB
$47.4M
| $8.03K | ﹤0.01% |
84
| – | – |
|
334
Theravance Biopharma
TBPH
$878M
| $7.83K | ﹤0.01% |
757
-156
| -17% | -$1.72K |
|
335
Arcutis Biotherapeutics
ARQT
$3.3B
| $7.67K | ﹤0.01% |
805
-23
| -3% | -$255 |
|
336
Harrow
HROW
$1.48B
| $7.52K | ﹤0.01% |
395
-8
| -2% | -$176 |
|
337
Editas Medicine
EDIT
$436M
| $7.45K | ﹤0.01% |
905
-30
| -3% | -$261 |
|
|
MRNS
338
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $7.19K | ﹤0.01% |
662
-10
| -1% | -$86 |
|
339
AnaptysBio
ANAB
$1.69B
| $7.06K | ﹤0.01% |
347
-38
| -10% | -$770 |
|
|
ME
340
DELISTED
23andMe Holding Co
ME
| $6.72K | ﹤0.01% |
192
-4
| -2% | -$159 |
|
|
TSVT
341
DELISTED
2seventy bio
TSVT
| $6.66K | ﹤0.01% |
658
+145
| +28% | +$1.53K |
|
342
Alector
ALEC
$240M
| $6.57K | ﹤0.01% |
1,093
-32
| -3% | -$223 |
|
|
TERN
343
DELISTED
Terns Pharmaceuticals
TERN
| $6.5K | ﹤0.01% |
743
+72
| +11% | +$839 |
|
|
ALPN
344
DELISTED
Alpine Immune Sciences Inc
ALPN
| $6.47K | ﹤0.01% |
629
+6
| +1% | +$54 |
|
345
Kiniksa Pharmaceuticals
KNSA
$6.1B
| $6.45K | ﹤0.01% |
458
-10
| -2% | -$134 |
|
346
Edgewise Therapeutics
EWTX
$4.73B
| $6.42K | ﹤0.01% |
829
-28
| -3% | -$236 |
|
347
Tarsus Pharmaceuticals
TARS
$3.07B
| $6.36K | ﹤0.01% |
352
-10
| -3% | -$159 |
|
348
Nautilus Biotechnolgy
NAUT
$114M
| $6.33K | ﹤0.01% |
1,637
-55
| -3% | -$158 |
|
349
Nurix Therapeutics
NRIX
$2.76B
| $6.21K | ﹤0.01% |
622
-19
| -3% | -$194 |
|
|
ITOS
350
DELISTED
iTeos Therapeutics
ITOS
| $6.21K | ﹤0.01% |
469
-13
| -3% | -$185 |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2023 Portfolio in Review
As of Q2 2023, China Universal Asset Management Company held 465 positions worth $324M, up 9.6% from $295M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
China Universal Asset Management Company's Q2 2023 filing shows 18 new, 159 increased, 243 reduced and 13 closed positions. Its largest new stake was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M. The largest sale was iQIYI, an estimated $5.11M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- China Universal Asset Management Company's largest Q2 2023 buy was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M.
- China Universal Asset Management Company added most to Alnylam Pharmaceuticals in Q2 2023, an estimated $1.96M increase.
- China Universal Asset Management Company's biggest Q2 2023 reduction was iQIYI, cutting an estimated $5.11M.
- China Universal Asset Management Company fully exited Block Inc in Q2 2023, selling an estimated $1.35M.
- China Universal Asset Management Company's ten largest holdings make up 33% of its $324M portfolio in Q2 2023.
- China Universal Asset Management Company opened 18 new positions and closed 13 in Q2 2023.
- China Universal Asset Management Company's portfolio value rose 9.6% quarter-over-quarter to $324M.
Based on China Universal Asset Management Company's 13F filing for Q2 2023, filed 28 Jul 2023.